ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
11.85
+0.03 (0.25%)
Nov 28, 2025, 4:00 PM EST - Market closed
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.
Employees
115
Change (1Y)
15
Growth (1Y)
15.00%
Revenue / Employee
n/a
Profits / Employee
-$1,176,261
Market Cap
1.15B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Dec 31, 2020 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORIC News
- 4 days ago - ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 15 days ago - ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates - GlobeNewsWire
- 15 days ago - ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety - GlobeNewsWire
- 21 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor - GlobeNewsWire
- 24 days ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors - GlobeNewsWire
- 3 months ago - ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha